We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Extreme Dieting Reduces Cardiac Risk in Diabetics

By HospiMedica International staff writers
Posted on 26 Dec 2011
Reducing calories intake to just 500 kcal per day may eliminate the need for insulin and improve heart function in some patients with type 2 diabetes, according to a new study. More...


Researchers at Leiden University Medical Center (LUMC; The Netherlands) studied 27 obese, insulin-dependent patients (14 men and 13 women, average age 55 years) with type 2 diabetes mellitus to investigate the effects of prolonged caloric restriction. The patients received a 16-week very low calorie diet (VLCD). Plasma lipids, lipoproteins, and plasma cholesteryl ester transfer protein (CETP) were measured at baseline and after 16 weeks. Functionality of high-density lipoprotein (HDL) with respect to inducing cholesterol efflux from human monocyte cells (THP-1) was also determined.

The results showed that a 16-week VLCD markedly decreased plasma CETP concentration and increased plasma apolipoprotein (apo)AI levels, without significantly affecting HDL-cholesterol and HDL-phospholipids. The results suggest that the VLCD diet may eliminate the need for insulin and improve heart function in some type 2 diabetics. The patients on the extreme diet also had significant improvement in diastolic function that was durable over 18 months, which correlated with the persistent reductions in pericardial fat. The study was published in the December 2011 issue of Diabetes Care.

“Lifestyle interventions may have greater cardiac benefits than medication. It's striking to see how a simple intervention like reducing caloric intake can diminish the need for insulin,” said study coauthor Sebastiaan Hammer, MD, PhD. “For the first days, coming off insulin is an effect of the diet itself; but afterward, it is an effect of losing weight.”

VLCDs are based on a formulated, nutritionally complete, liquid meal containing 800 kcal or less per day, but contain the recommended daily requirements for vitamins, minerals, trace elements, fatty acids, and protein. Carbohydrate may be entirely absent, or substituted for a portion of the protein; this choice has important metabolic effects. The VLCD is prescribed on a case-by-case basis for rapid weight loss (about 1.5-2.5 kilograms per week) in patients with a body mass index (BMI) of 30 and above.

Related Links:
Leiden University Medical Center



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.